NCT07144111View on ClinicalTrials.gov

A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib

PHASE1RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 21, 2025

Primary Completion Date

September 6, 2026

Study Completion Date

September 6, 2026

Conditions
Hepatic Impairment
Interventions
DRUG

Inavolisib

Participants will receive a single oral dose of inavolisib

Trial Locations (4)

32809

RECRUITING

Orlando Clinical Research Center, Orlando

78215

RECRUITING

The Texas Liver Institute, Inc., San Antonio

78229

RECRUITING

Pinnacle Clinical Research - San Antonio, San Antonio

92630

RECRUITING

Orange County Research Center, Lake Forest

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY